Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Abstract

PURPOSE Nivolumab and pembrolizumab are antibodies against the programmed-death-receptor- 1 (PD-1) which are associated with distinct immune related adverse effects (AEs). This meta-analysis of randomized clinical trials aims to summarize current knowledge regarding the toxicity profile of these agents. METHODS PubMed search was conducted in February of… (More)
DOI: 10.18632/oncotarget.13315

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Costa2017ToxicityPO, title={Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials}, author={Ricardo Costa and Benedito A. Carneiro and Mark Agulnik and Alfred W. Rademaker and Sachin Gopalakrishna Pai and Victoria Villaflor and Massimo Cristofanilli and Jeffrey A. Sosman and Francis Joseph Giles}, booktitle={Oncotarget}, year={2017} }